Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer

作者
Paul Zarogoulidis,Theodoros Kontakiotis,Karaiskos,Boutsikou,Konstantinos Zarogoulidis,Sakas,Darwiche,Wolfgang Hohenforst‐Schmidt,Kosmas Tsakiridis,Galaktidou,Κonstantinos Porpodis,Eleftheriadou
出处
期刊:OncoTargets and Therapy [Dove Medical Press]
卷期号:6: 125-125 被引量:44
标识
DOI:10.2147/ott.s42245
摘要

BACKGROUND: Bevacizumab and erlotinib have been demonstrated to prolong overall survival in patients with non-squamous non-small cell lung cancer (NSCLC). We designed a four-arm Phase III trial to evaluate the efficacy and toxicity of the combination of docetaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with NSCLC. METHODS: A total of 229 patients with stage IIIb/IV non-squamous NSCLC were treated with two cycles of carboplatin (area under the concentration-time curve 5.5) and docetaxel 100 mg/m2 as chemotherapy. After completion of two treatment cycles, patients were evaluated for response and divided into four groups: 61/229 continued with four more cycles of chemotherapy (control group), 52/229 received chemotherapy plus erlotinib 150 mg daily, 56/229 received chemotherapy plus bevacizumab 7.5 mg/kg, and 60/229 were treated with the combination of chemotherapy, erlotinib, and bevacizumab until disease progression. The primary endpoint was overall survival. RESULTS: Over 4 years of follow-up, there was no statistically significant difference in survival and time to progression between the four treatment groups. After two cycles of chemotherapy, responders and nonresponders were divided according to their response in order to examine the role of initial response as an independent factor in survival and response when a biological agent is combined with chemotherapy. Nonresponders, who received additional therapy with bevacizumab or combination therapy, had a survival benefit [657 days (95% confidence interval 349-970) and 681 days (95% confidence interval 315-912), respectively], which was statistically significant compared with continuation of cytotoxic chemotherapy (P < 0.001). The combination therapy had a safety profile comparable with that of bevacizumab and erlotinib taken individually. CONCLUSION: Administration of bevacizumab and erlotinib in combination with first-line chemotherapy, followed by bevacizumab and erlotinib monotherapy as maintenance, showed promising results in patients with NSCLC, with reduced toxicity as compared with chemotherapy alone, but did not translate into longer overall survival.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
yy完成签到,获得积分10
1秒前
2秒前
lxl完成签到,获得积分10
3秒前
3秒前
dlxxx完成签到,获得积分20
3秒前
风吹麦浪的应助被禾乃采纳,获得10
3秒前
4秒前
4秒前
4秒前
123完成签到,获得积分10
4秒前
南柯发布了新的文献求助10
4秒前
谦让音响发布了新的文献求助10
5秒前
张楠完成签到,获得积分10
5秒前
易易发布了新的文献求助10
5秒前
zhuwei发布了新的文献求助10
6秒前
lifan发布了新的文献求助10
6秒前
娓鸢发布了新的文献求助10
6秒前
云念完成签到,获得积分10
6秒前
7秒前
nike胡咧咧完成签到,获得积分10
8秒前
丘比特的应助被randong采纳,获得10
8秒前
8秒前
saturn发布了新的文献求助10
9秒前
9秒前
里打动完成签到,获得积分10
10秒前
Yaya发布了新的文献求助10
10秒前
oddar发布了新的文献求助20
10秒前
阳光绿柏完成签到,获得积分10
11秒前
彭于晏的应助被权瑞松采纳,获得30
11秒前
orixero的应助被lei采纳,获得10
11秒前
Scarlett2完成签到,获得积分10
12秒前
12秒前
Nole的应助被忧郁鸿煊采纳,获得30
13秒前
Liucky发布了新的文献求助10
13秒前
卢小妹发布了新的文献求助10
13秒前
13秒前
思川发布了新的文献求助10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193361
求助须知:如何正确求助?哪些是违规求助? 9579602
关于积分的说明 21866201
捐赠科研通 7792983
什么是DOI,文献DOI怎么找? 3437263
关于科研通互助平台的介绍 2560718
邀请新用户注册赠送积分活动 2484082